Health Condition 1: F321- Major depressive disorder, singleepisode, moderate
Conditions
Interventions
Intervention1: Memantine: The patients currently on Escitalopram 10-20 mg/day will be randomly allocated into 2 groups of 30 each receiving either Memantine 10 mg or the placebo
Control Intervention1:
Sponsors
Dayanand Medical college and hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1.The patients with a diagnosis of Major depressive disorder according to DSM-5 criteria presenting to Department of Psychiatry,DMC&H, Ludhiana 2.Age group 60-99 years 3.Score of more than or equal to 16 on the 24-item Hamilton Rating Scale for Depression (HAM-D) 4.Score of more than 5 on Geriatric Depression Scale 5.Patients who have given consent for the study
Exclusion criteria
Exclusion criteria: 1.History of any other major psychiatric disorder 2.Recent or current unstable medical or neurological disorder 3.Diagnosis of moderate/severe cognitive impairment and patients with dementia (Dementia screening by Clinical Dementia Rating Score of 0.5) 4.Known allergic reaction to Escitalopram or Memantine 5.Patients who have not given consent for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome will be assessed on Hamilton Depression Rating Scale (HAM-D) and GDS-15.Timepoint: Depressed mood and neurocognitive function will be judged in the beginning,3 weeks and at the end of the study and the scores will be compared. | — |
Secondary
| Measure | Time frame |
|---|---|
| Neurocognitive function assessmentTimepoint: Neurocognitive function will be judged in the beginning,3 weeks and at the end of the study | — |
Countries
India
Contacts
Public ContactDr Navkiran S Mahajan
Dayanand Medical college and hospital
Outcome results
None listed